Episode

Discussing PsA: Uveitis risk and treatment sequencing outcomes in axSpa and PsA

Podcast: The IMID Forum
Published: Dec 4, 2025
Duration seconds: 1247
Processing state: not_requested
Canonical source: https://soundcloud.com/imidforum/discussing-psa-uveitis-risk-and-treatment-sequencing-outcomes-in-axspa-and-psa
Audio: https://feeds.soundcloud.com/stream/2222625149-imidforum-discussing-psa-uveitis-risk-and-treatment-sequencing-outcomes-in-axspa-and-psa.mp3
JSON: /v1/public/podcasts/the-imid-forum-981476/episodes/discussing-psa-uveitis-risk-and-treatment-sequencing-outcomes-in-axspa-and-psa
Markdown: /podcast/the-imid-forum-981476/discussing-psa-uveitis-risk-and-treatment-sequencing-outcomes-in-axspa-and-psa.md

Actions

POST https://stenobird.com/v1/public/podcasts/the-imid-forum-981476/episodes/discussing-psa-uveitis-risk-and-treatment-sequencing-outcomes-in-axspa-and-psa/transcription-requests
Idempotently request low-priority transcript generation for this episode.
GET https://stenobird.com/podcast/the-imid-forum-981476/discussing-psa-uveitis-risk-and-treatment-sequencing-outcomes-in-axspa-and-psa.md
Read the agent-friendly Markdown representation of this episode resource.

Summary

Join Professor Laura Coates and Phillip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered the ‘the effectiveness and safety of upadacitinib with secukinumab and adalimumab’ and ‘the efficacy of long-term treatment with risankizumab across the updated GRAPPA domains and key related conditions of PsA’.